Endogenous and synthetic MMP inhibitors in CNS physiopathology.

Baranger, Kévin; Rivera, Santiago; Liechti, Fabian D; Grandgirard, Denis; Bigas, Judit; Seco, Jesús; Tarrago, Teresa; Leib, Stephen; Khrestchatisky, Michel (2014). Endogenous and synthetic MMP inhibitors in CNS physiopathology. In: Dityatev, Alexander; Wehrle-Haller, Bernhard; Pitkänen, Asla (eds.) Brain Extracellular Matrix in Health and Disease. Progress in Brain Research: Vol. 214 (pp. 313-351). Elsevier 10.1016/B978-0-444-63486-3.00014-1

Text Endogenous and synthetic MMP inhibitors in CNS physiopathology.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Matrix metalloproteinases (MMPs, including the membrane-type MMPs (MT-MMPs)), a disintegrin and metalloproteinase (ADAM), and ADAM with thrombospondin motifs belong to the metzincins, a subclass of metalloproteinases that contain a Met residue and a Zn(2+) ion at the catalytic site necessary for enzymatic reaction. MMP proteolytic activity is mainly controlled by their natural tissue inhibitors of metalloproteinase (TIMP). A number of synthetic inhibitors have been developed to control deleterious MMP activity. The roles of MMPs and some of their ECM substrates in CNS physiology and pathology are covered by other chapters of the present volume and will thus not be addressed in depth. This chapter will focus (i) on the endogenous MMP inhibitors in the CNS, (ii) on MMP and TIMP regulations in three large classes of neuropathologic processes (inflammatory, neurodegenerative, and infectious), and (iii) on synthetic inhibitors of MMPs and the perspective of their use in different brain diseases.

Interest & Impact

Downloads

4 since deposited on 06 Feb 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item